Human Cardiac Organoids: Advances and Prospects from Construction to Preclinical Drug Evaluation. [PDF]
Chen M +9 more
europepmc +1 more source
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation. [PDF]
Serra-Camprubí Q +30 more
europepmc +1 more source
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee +3 more
wiley +1 more source
Microbiota-gut-brain axis multi-organ chip construction and applications in drug evaluation. [PDF]
Tang Y +9 more
europepmc +1 more source
Live-cell imaging-based dynamic vascular formation assay for antivascular drug evaluation and screening. [PDF]
Li Z +8 more
europepmc +1 more source
Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley +1 more source
Clinical Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors for the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer Based on the 2nd Edition of China's Drug Evaluation and Selection Guideline. [PDF]
Guo Z +9 more
europepmc +1 more source
Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim +7 more
wiley +1 more source
FDA and EMA approval of datopotamab-deruxtecan: A paradigm shift in breast cancer drug evaluation? [PDF]
Orlandi A.
europepmc +1 more source

